COGENT BIOSCIENCES INC (COGT)

US19240Q2012 - Common Stock

6.72  +0.2 (+3.07%)

After market: 6.72 0 (0%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

COGENT BIOSCIENCES INC

NASDAQ:COGT (3/28/2024, 7:04:54 PM)

After market: 6.72 0 (0%)

6.72

+0.2 (+3.07%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap698.28M
Shares
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

COGT Daily chart

Company Profile

Cogent Biosciences, Inc. is a biotechnology company, which engages in the development of precision therapies for genetically defined diseases. The company is headquartered in Waltham, Massachusetts and currently employs 138 full-time employees. The company went IPO on 2018-03-29. The Company’s advanced clinical program, bezuclastinib (CGT9486), is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17 found within the KIT receptor tyrosine kinase, including KIT D816V. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. In addition to bezuclastinib, the Company is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases. The firm has initiated APEX, a Phase II clinical study of bezuclastinib in patients with AdvSM. APEX is an open-label, global, multicenter study evaluating the safety, efficacy, pharmacokinetic, and pharmacodynamic profiles of bezuclastinib.

Company Info

COGENT BIOSCIENCES INC

275 Wyman Street, 3rd Floor

Waltham MASSACHUSETTS 02140

P: 16179455576

CEO: Andrew Robbins

Employees: 138

Website: https://www.cogentbio.com/

COGT News

News Imagea month ago - Seeking AlphaCogent downgraded at Baird on rare disease drug data (NASDAQ:COGT)

Baird downgrades Cogent Biosciences to neutral as disappointing data for bezuclastinib raises concerns. Read more here.

News Imagea month ago - Cogent Biosciences, Inc.Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results

•   UMMIT Part 2 registration-directed study of bezuclastinib in NonAdvSM patients initiated and actively enrolling at 40 sites globally; once-daily 100 mg...

News Imagea month ago - Seeking AlphaCogent Biosciences stock jumps on Phase 2 data for bezuclastinib (NASDAQ:COGT)

Cogent Biosciences (COGT) stock jumped 10% Thursday after the company reported positive data for its drug candidate bezuclastinib in the treatment of NonAdvSM. Read more here.

News Imagea month ago - Cogent Biosciences, Inc.Cogent Biosciences Announces Positive Part 1b Data from SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis

Registration-enabling SUMMIT Part 2 initiated and actively enrolling at 40 sites globally; RP2D selected at 100 mg once-daily optimized formulation based...

News Imagea month ago - Market News VideoBullish Two Hundred Day Moving Average Cross - COGT
News Imagea month ago - Seeking AlphaCogent Biosciences announces oversubscribed $225M private placement (NASDAQ:COGT)

Cogent Biosciences has entered into a private investment in public equity financing, raising $225 million to fund R&D activities and general corporate...

COGT Twits

Here you can normally see the latest stock twits on COGT, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example